Background/Aims: Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug is used to treat epileptic seizure of glioblastoma patients. Besides its antiepileptic activity, VPA has been attributed further functions that improve the clinical outcome of glioblastoma patients. Those comprise the inhibition of some histone deacetylase (HDAC) isoforms which reportedly may result in radiosensitization. Retrospective analysis of patient data, however, could not unequivocally confirm a prolonged survival of glioblastoma patients receiving VPA. The present study aimed to identify potential VPA targets at the cellular level. Methods: To this end, the effect of VPA on metabolism, Ca 2+ -, biochemical and electro-signaling, cell-cycling, clonogenic survival and transfilter migration was analyzed in three human glioblastoma lines (T98G, U-87MG, U251) by MTT assay, Ca 2+ imaging, immunoblotting, patch-clamp recording, flow cytometry, delayed plating colony formation and modified Boyden chamber assays, respectively. In addition, the effect of VPA on clonogenic survival of primary glioblastoma spheroid cultures treated with temozolomide and fractionated radiation was assessed by limited dilution assay. Results: In 2 of 3 glioblastoma lines, clinical relevant concentrations of VPA slightly slowed down cell cycle progression and decreased clonogenic survival. Furthermore, VPA induced Ca 2+ signaling which was accompanied by pronounced K + channel activity and transfilter cell migration. VPA did not affect metabolic NAD(P)H formation or radioresistance of the glioblastoma lines. Finally, VPA did not impair clonogenic survival or radioresistance of temozolomide-treated primary spheroid cultures. Conclusions: Combined, our in vitro data do not propose a general use of VPA as a radiosensitizer in anti-glioblastoma therapy.
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Introduction
The standard therapy for glioblastoma multiforme patients consist of surgical resection followed by radiation therapy and concomitant chemotherapy with temozolomide, an alkylating agent that methylates DNA and that is most effective in glioblastomas with methylated promotor of the O-6-methylguanine-DNA methyltransferase (MGMT) gene [1, 2] . Therapy failure observed in the vast majority of glioblastoma patients and bad prognosis are probably due to a high intrinsic resistance to chemo-and radiotherapy on the one hand and on the fast spreading of glioblastoma cells in the brain on the other. Up to 50% of glioblastoma patients develop tumor-associated epileptic seizures that are treated with antiepileptic drugs such as valproic acid (VPA) [3] . In the human brain, VPA potentates the inhibitory activity of the neurotransmitter GABA, attenuates NMDA receptor-mediated excitation, and may block voltage-gated Na + -, Ca 2+ -, and K + channels (for review see [4, 5] ). In addition to its anticonvulsive action, VPA has been demonstrated to inhibit histone deacetylases (HDAC, for review see [6] ) suggesting that histone hyperacetylation might occur during VPA therapy and might contribute to the anticonvulsive VPA effect. Along those lines, the VPA-induced histone hyperacetylation has been proposed to contribute to teratogenic side effects of VPA [7] possibly together with the VPA action as antimetabolite to folic acid and VPA-induced oxidative stress [8] .
Histone deacetylase inhibitors have been demonstrated to modify chromatin structure, gene expression, and to radiosensitize tumor cells [9] . As a matter of fact, VPA-mediated radiosensitization of glioblastoma cells has been observed in vitro and in preclinical in vivo studies [10] [11] [12] [13] [14] [15] . VPA-mediated HDAC inhibition has been demonstrated to induce replicationindependent active DNA demethylation [16] . DNA demethylation, however, might induce upregulation of MGMT expression and might confer resistance to temozolomide. In contrast to this assumption, VPA has been shown to down-regulate MGMT expression in glioma cells [17] and to sensitize glioblastoma cells to temozolomide in vitro in some [11, 17, 18] but not all [19] studies (for review see [20] .
Beyond radio-and temozolomide sensitization, VPA-mediated histone hyperacetylation and DNA demethylation are associated with changes in cell morphology, decrease cell viability and increase apoptosis rates [14, 19, 21, 22] . Moreover, VPA treatment of glioma cells has been demonstrated to boost the adaptive immune response. Vaccination with VPAtreated glioma cells, however, did not improve mouse survival in syngeneic glioma mouse models [23] In accordance with these results, retrospective (meta-)analysis [24] [25] [26] [27] [28] [29] [30] of patient data and a single-armed phase-2 clinical trial [31] suggested prolonged survival of glioblastoma patients receiving VPA. A meta study analyzing the largest cohort (1,800 patients), in sharp contrast, could not confirm that VPA treatment of newly diagnosed glioblastoma patients associates with longer progression-free and overall survival [32] . A further multivariate analysis of 647 patients with de novo glioblastoma identified epilepsy as a prognostic factor for longer survival. Epileptogenic tumors exhibited significantly smaller volumes than those of non-epileptogenic ones probably due to earlier detection [33] . Nevertheless, epilepsy cannot be attributed solely to early diagnosis since it was associated with better prognosis independently of tumor volume in multivariate analysis. In glioblastoma patients presenting with epilepsy, however, VPA treatment did not associate with survival [33] again challenging the value of VPA in anti-glioblastoma therapy. The conclusiveness of these studies is debated since they are retrospective in nature with limited correction for confounders, and the dosages and duration of VPA treatment were often not defined [34] . Moreover, some the studies have low statistical power due to small patient cohorts or leave epilepsy as prognostic factor per se out of consideration. [33] .
Combined, these conflicting results do not allow to define conclusively the benefit (besides its anticonvulsive action) of VPA for anti-glioblastoma therapy. The present study, therefore, aimed to collect further data on the effect of VPA in glioblastoma at a cellular level by analyzing VPA-induced modification of signaling, physiology and radiation biology.
Material and Methods
Human glioblastoma cell lines T98G and U-87MG were grown in RPMI-1640, human U251 glioblastoma cells in DMEM (4.5 g glucose/l). Both media were supplemented with 10% fetal bovine serum (FBS). All experiments with these cell lines were performed with exponentially growing cultures. For primary spheroid cultures, resected glioblastoma tissue (patients gave informed consent and this study has been approved by the local ethic committee under project# 579/2015BO2) was dissociated enzymatically and mechanically and plated in Complete NeuroCult™ NS-A Proliferation medium containing 20 ng/ml rh EGF, 10 ng/ml rh bFGF and 0.0002% heparin (STEMCELL Technologies Germany GmbH, Cologne, Germany). Tumor specimens (LK-XI, LK-XII, and LK-XIII) from two male and a female patient (72-74 years old) with according to the pathology report confirmed grade IV astrocytoma (glioblastoma) and wildtype isocitrate dehydrogenase-I status were used. In one of these specimens (specimen LK-XII) the O-6-methylguanine-DNA methyltransferase (MGMT) gene was downregulated epigenetically, not so in the other two specimens. Every second day, 1/10 of the original medium volume of the primary spheroid culture was replenished. Valproic acid (VPA, Sigma, Deisenhofen, Germany) was prepared in 100 mM stock solution in the respective media or NaCl solution (125 mM NaCl, 32 mM Hepes/NaOH, pH 7.4, 5 mM KCl, 5 mM d-glucose, 1 mM CaCl 2 , 1 mM MgCl 2 ). A 10 mM and a 100 mM stock solution of paxilline and temozolomide (both Sigma), respectively, were prepared in DMSO.
To analyze the effect of VPA treatment on metabolism, exponential growing T98G, U251 and U-87MG cells (750 cells/well) were treated for 48 h with 0-1000 µM VPA. Thereafter, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma) transformation to formazane was determined photometrically as a measure of metabolic NAD(P)H turnover.
Fura-2 Ca 2+ imaging was performed as described [35] in U251 cells superfused with NaCl solution before, during, and after administration of VPA (750 µM). Immunoblotting of VPA (0 or 750 µM for 48 h)-treated U251 cells was carried out according to [36] with the following antibodies: anti-cdc25A (#3652S, Cell Signaling, Danvers, USA), anti-p(S124)-cdc25A (#T1155, epitomics, Burlingame, USA), anti-cdc25B (#9525S Cell Signaling), anti-p(Ser187)-cdc25B (#T1162, epitomics), anti-cdc25C (#4688S, Cell Signaling), p(S216)-cdc25C (#4901S, Cell Signaling), cdc2 (#9112S, Cell Signaling) and p(Tyr15)-cdc2 (#9111S, Cell Signaling, all 1:500) and anti-β-actin (clone AC-74, #A2228, Sigma, 1: 20.000).
Cell cycle distribution (after 48 h and 72 h treatment with 0, 250 or 750 µM VPA) of T98G, U251 and U-87MG cells and clonogenic survival (after 1 h pre-incubation, irradiation with 0, 2, 4, or 6 Gy 6 MV, and 24 h post-incubation all in the presence of 0 and 750 µM VPA, respectively) were determined by flow cytometry and delayed plating colony formation assay, respectively, essentially as described [37] . VPA (0 or 750 µM)-stimulated ion channel activity and transfilter chemotaxis were assessed in T98G and U251 cells by patch-clamp on-cell recording (using NaCl solution in bath and pipette) and real-time impedance recording (xCELLigence system, Roche, Mannheim, Germany), respectively, essentially as described [37] .
To determine clonogenic survival of primary glioblastoma by limited dilution assay, spheroids were dissected mechanically into single cells and 2500 cells were sequentially 1:2-diluted. Dilution were performed in 100 µl Complete NeuroCult™ NS-A Proliferation medium (STEMCELL Technologies Germany GmbH, Cologne, Germany) additionally containing temozolomide (5 µM in 0.005% DMSO) and VPA (0 or 750 µM). Starting 1 h after sequential dilution and onset of temozolomide and VPA treatment, cells were fractionated irradiated applying a total dose of 0 or 10 Gy (6 MV photons) in 5 fractions of 2 Gy on 5 consecutive days. After further 6 week of incubation in the presence of temozolomide (5 µM) and VPA (0 or 750 µM) minimal cell number required to sustain the primary culture was determined as a measure of clonogenic survival.
Data are means ± SE and statistical analysis was made by normal or Welch-corrected two-tailed unpaired or paired t-test, parametric ANOVA using Tukey´s post hoc test, or Kruskal-Wallis test (nonparametric ANOVA) where appropriate. *, **, and *** indicate p ≤ 0.05, 0.01 and 0.001, respectively. in the glioblastoma cell lines T98G, U251 and U-87MG. To define the effect of VPA on metabolic NAD(P)H formation, MTT dehydrogenase activity was measured in the presence of increasing concentrations of VPA (100 µM -1 mM). In all three glioblastoma cell lines, VPA inhibited MTT dehydrogenase activity at concentrations ≥ 800 µM with apparent IC 50 of 1.4, 1.0, and 1.3 mM in T98G, U251 and U-87MG cells, respectively (Fig. 1) .
To test for VPA-triggered signaling events, cytosolic free Ca 2+ concentration was measured in all three glioblastoma cell lines by fura-2 Ca 2+ imaging before, during acute administration and upon wash-out of VPA (750 µM). As shown in Fig. 2A , B, VPA stimulated a prominent long-lasting increase in intracellular free Ca 2+ concentration in U251 cells. In U-87MG cells, in contrast, VPA evoked only a minute but significant (p ≤ 0.001) Ca 2+ increase (fura-2 fluorescence ratio increased from 0.63 to 0.64, n = 136) while in T98G cells (n = 126) VPA did not exert any apparent effect (data not shown).
In -activated K + channels [38] . CaMKII, in turn, has been reported to regulate the cell cycle via inactivation of cdc25 isoforms and subsequent inactivation of cdc2 (CDK1) [39] [40] [41] [42] . To define putative Ca
2+
-mediated VPA effects on cell cycle, VPA (0 or 750 µM for 48 h)-treated U251 cells were probed against cdc25A, -B, -C and cdc2 as well as against the phosphorylated forms of these proteins by immunoblotting. VPA did not alter abundances of total or phosphorylated cdc25B and -C (data not shown). In contrast, VPA stimulated phosphorylation of cdc25A ( Fig. 2C-E) and accumulation of the phosphorylated and inactive form of cdc2 ( Fig. 2F-H) . Together, these experiments indicate that VPA may interfere with signaling and cell cycle regulation in glioblastoma cells.
Next, the effect of VPA (0, 250 or 750 µM for 48h and 72 h, respectively) on cell cycle was analyzed in flow cytometry experiments by determining the DNA content of permeabilized glioblastoma cells with the fluorescent dye propidium iodide (Fig. 3A) . As a result, VPA did not modify cell cycling of T98G cells (Fig. 3A , left, and 3B, E). In U251, in contrast, VPA (750 µM) significantly increased S (72 h VPA) and G 2 population (48 h and 72 h VPA). The latter effect was also seen after 72 h treatment with the lower VPA dose (250 µM, Fig. 3C, F) . Similarly, in U-87MG cells VPA (750 µM) significantly decreased G 1 population (48 h VPA) and increased S (48 h and 72 h VPA) and G 2 population (72 h VPA, Fig. 3A , right, and 3D, G). Together, this points to a VPA-induced S and G 2 /M cell cycle arrest in U251 and U-87MG cells.
To determine, whether this VPA-mediated cell cycle interference might radioprotect or radiosensitize glioblastoma cells, colony formation was measured in all three glioblastoma cell lines upon irradiation (0, 2, 4 and 6 Gy 6 MV photons). Cells were pre-incubated (1h), irradiated and post-incubated (24 h) with VPA (0 or 750 µM) before plating the cells in VPA- 
free medium for colony formation. In neither cell line, VPA modified radiosensitivity (Fig.  4A-C, left and right) . In U251 and U-87MG but not in T98G cells VPA lowered the plating efficiency by some 20% (Fig. 4A-C, middle) . Combined, these data suggest that VPA may impair clonogenic survival and slow-down cell cycle progression. VPA, however, does not seem to interfere with the stress response of glioblastoma cell lines following cell injury by ionizing radiation. Finally, VPA effects on glioblastoma cell physiology were characterized. Ca 2+ signaling has been demonstrated to stimulate BK K + channel activity in glioblastoma cells [37] . Cell volume changes and electrosignaling by BK K + channels, in turn, have been identified as key regulators of glioblastoma cell migration [37, 38] . Therefore, VPA-dependent changes in BK K + channel activity and transfilter chemotaxis were assessed in T98G and U251 cell lines by patch-clamp on-cell recording (Fig. 5A-G) and by the use of a modified Boyden chamber (Fig.  5H, I ), respectively.
Acute administration of VPA (750 µM) stimulated outward current transitions with large unitary conductance in T98G and U251 cells (Fig. 5B, C , left and middle) that were blocked by the BK K + channel-specific inhibitor paxilline (Fig. 5B, C, right) . These VPAstimulated current transitions generated in both glioblastoma cell lines an outwardly rectifying macroscopic on-cell current at depolarized voltages (Fig. 5D, F) which gave rise to a significant increase in membrane conductance (Fig. 5E, G) . Large unitary conductance, paxilline sensitivity, and voltage-dependent activation that results in outward rectification of the generated currents are typical features of BK K + channels [38] indicating VPA-stimulated BK K + channel activation. Elevated BK K + channel activity was paralleled by a VPA (750 µM)-stimulated acceleration of transfilter chemotaxis in T98G cells triggered by a 1%-to-5% FBS gradient (Fig. 5H) . Notably, in U251 cells VPA (750 µM) exerted comparable similar stimulatory effects on transfilter chemotaxis cells only upon a 5 h to 48 h pretreatment with VPA (Fig.  5I) . In summary, these experiments on human glioblastoma cell lines suggest that VPA may stimulate electrosignaling and migration of human glioblastoma cells. To test possible VPA effects on glioblastoma radio-and chemosensitivity in an experimental setting that resembles more the clinical situation, we grew primary spheroids from glioblastoma resectates (LK-XI, LK-XII, LK-XIII) in FBS-free stem cell medium. In these spheroids the minimal number of cells required to sustain the primary culture as a measure of clonogenicity was determined in the continuous presence of temozolomide in dependence on fractionated irradiation (5 x 0 Gy or 5 x 2 Gy) and VPA (0 or 750 µM) by pre-plating limited dilution assay (Fig. 6A, B) . According to the Stupp protocol [2] , glioblastoma patients are treated with 75 mg/m 2 temozolomide concomitant to fractionated radiotherapy and with 150 mg/m 2 for the subsequent maintenance chemotherapy. Patients receiving temozolomide (150 mg/m 2 ) have been shown by intracerebral microdialysis to accumulate 1.2 -3.4 h after drug administration maximal temozolomide concentrations in the brain interstitial fluid of 1.1 -5.7 µM [43] . Therefore, we chose a concentration of 5 µM temozolomide added to the FBS-free medium for the limited dilution assay. As a result, minimal cell numbers required to sustain the primary cultures in the presence of temozolomide differed markedly between the individual glioblastoma cultures. In particular, the glioblastoma (LK-XII) specimen with epigenetic silencencing of the temozolomide resistance gene MGMT [44] (Fig. 6B , middle) required 5-10 times more cells to sustain clonogenic survival in the presence of temozolomide than the two other glioblastomas (LK-XI and LK-XIII) without MGMT promoter methylation (Fig. 6B, top and bottom) . Fractionated irradiation (5 x 2 Gy) decreased in all three glioblastoma cultures the clonogenic survival to about 20% of the non-irradiated cells (i.e., 5 times more cells were required to sustain the culture (Fig. 6B, open bars) . Importantly, VPA (750 µM) had no (LK-XII) or only very little and insignificant (LK-XI and LK-XIII) radio-/ chemosensitizing effects on clonogenic survival Fig. 6B , compare open with closed bars). Hence, these experiments on primary spheroids confirmed in a more clinically relevant setting the low VPA effects observed in the experiments on human glioblastoma cell lines described above.
Discussion
Valproic acid is an approved drug for the treatment of epileptic seizures but also off-label prescribed against migraine, depression, anxiety, psychotic disorders, alcohol withdrawal and dependence, dementia associated agitation, and borderline personality disorders [45, 46] . During chronic oral treatment with 15-20 mg/kg VPA per day, epilepsia patients accumulate total plasma concentrations in the range of 0.3-0.7 mM (for review see [4] ). In human beings, a high fraction of VPA binds to serum albumin. As a consequence, lower VPA concentrations of around 40-200 µM at a daily VPA treatment of 15-20 mg/kg are observed in the brain indicating VPA brain/plasma ratios in the range of 0.07 to 0.28. (for review see [4] ). A dose escalation study in glioma patients defined 60 mg/kg VPA per day as maximal tolerable dose which gave rise to median plasma concentrations of about 0.85 mM and a maximal plasma concentration not exceeding 1.4 mM [47] . Taking the highest estimated brain/plasma ratio of 0.28 [4] as a basis, this translates to a maximal VPA concentration in the brain of 400 µM under dose-escalation. Combined, this suggests a "therapeutic", i.e., anticonvulsive VPA concentration of ≤200 µM in the brain which maximally can be doubled by dose escalation. This further suggests that preclinical studies applying VPA concentrations of 1 mM or above most probably do no more mirror the clinical situations especially when the in vitro experiments were done under serum-free experimental conditions where the total equals the free, i.e., effective VPA concentration. VPA in the present in vitro study did not impair metabolic NAD(P)H formation of human U-87MG, T98G and U251 glioblastoma cells at concentrations of <800 µM (see Fig.  1 ). In addition, VPA at a concentration of 750 µM did not radiosensitize the three human glioblastoma cell lines and three primary glioblastoma spheroid cultures studied in delayed plating colony formation assays and pre-plating limited dilution assays, respectively. These results were unexpected in light of the reported chromatin remodeling action of VPA [18, [48] [49] [50] and contradictory to previous in vitro studies [10] [11] [12] [13] [14] [15] 17 [22] were applied in these studies.
In particular, in delayed-or pre-plating colony formation assays VPA concentrations of 2.5 mM, 1.5 mM, and 3 mM have been reported to radiosensitize T98G cells (24 h and 48 h VPA pre-incubation, VPA co-incubation during irradiation, and VPA-free post-incubation [11] ), U251 cells (30 h VPA pre-incubation and VPA co-incubation during irradiation, and VPA post-incubation [10] ), and U-87MG cells (18 h VPA pre-incubation, VPA co-incubation during irradiation, VPA-free post-incubation [12] ), respectively. In the present study, VPA (750 µM) failed to radiosensitize T98G, U251 and U-87MG in delayed plating colony formation assays (1 h VPA-pre-incubation, VPA co-incubation during irradiation, and 24 h VPA postincubation). Likewise, in the present experiments on primary glioblastoma spheroid cultures subjected to fractionated irradiation (5 x 0 Gy or 5 x 2 Gy) and temozolomide (5 µM), VPA (750 µM) neither impaired clonogenic survival nor radiosensitized the cells while a previous study using higher VPA concentrations (1-15 mM) in a similar experimental setting (primary glioblastoma cultures, irradiation, temozolomide) reported VPA-mediated inhibition of cell viability by MTT assay [13] .
These apparent discrepancies between the previous reports and the present study might result from the different protocols applied. They might also hint to a difference in histone hyperacetylation status. The glioblastoma data base of the The Cancer Genome Atlas suggests that individual glioblastoma specimens differ markedly in their pattern of HDAC isoform expression (see Fig. 7A ). In particular, glioblastoma specimens, primary cultures and cell lines reportedly over-express histone deacetylases HDAC1, -3, -6, -9 and the class III histone deacetylase SIRT2 when compared to normal brain tissue. Importantly, HDAC3, -9, and SIRT2 expression levels in the tumor have been associated with poor survival of the glioblastoma patients (for review see [6] ). Since VPA has been shown to inhibit class-I and -II HDACs with IC 50 values ranging from 150-700 µM for HDAC1 [54, 55] , 1.0-5.5 mM [54, 55] for HDAC3, and >20 mM for HDAC6 [55] , respectively (also see Fig. 7A ), one might speculate that small variation of the VPA concentration in this range may result in significant changes of HDAC inhibition. Therefore, the higher VPA concentrations used in the previous in vitro studies [10] [11] [12] might have induced radiosensitizing histone hyperacetylation while the lower VPA concentration applied in the present study did not. If so, VPA concentrations of 40-200 µM (400 µM) usually accumulating in the brain of epilepsy patients (see above) would be expected to promote radiosensitizing histone hyperacetylation only if an individual glioblastoma expresses a high ratio between VPA-sensitive (e.g., HDAC1) and -insensitive (e.g., HDAC6) HDACs. This ratio may differ markedly between individual glioblastoma specimens as shown for the mRNA abundances of HDAC3 and HDAC6 in Fig. 7B . In contrast to human cells, VPA-induced radiosensitization at concentrations as low as 600 µM has been demonstrated in C6 rat glioma cells by colony formation assay [10, 51] which might hint to expression of more VPA-sensitive histone deacetylase isoforms in rodent cells.
Finally, one have to bear in mind that VPA is an organic acid with a pK a value of 4.56 [4] deducing that 0.14% of VPA exists as protonated uncharged acid (H-VPA) at physiological pH. Since H-VPA is highly lipophilic (log octane/water partition coefficient = 2.29), H-VPA can freely cross the plasma membrane and acidifies the cytoplasm. Therefore, it can be assumed that reported in vitro experiments using several millimolar VPA concentrations confer unspecific cellular pH stress and -if not controlled properly -additional physiologically relevant osmotic stress which might impact on radiation and temozolomide sensitivity and trigger cellular stress responses that are different from the pharmacology of VPA in the clinical situation.
Along those lines, in preclinical ectopic glioblastoma mouse models, treating irradiated (single fraction of 4 Gy [10] or 4 fractions of 3 Gy [12] ) human xenografts with VPA (daily i.p. administration of 2 x 150 mg/kg over 3 [10] or 6 days [12] ) delayed tumor growth when compared to irradiation alone while VPA-treatment of unirradiated tumors had no effect. Pharmacokinetics differ markedly between mouse and human beings. For instance, only 12% of VPA in mouse plasma are bound to plasma protein while 80-95% do so in human plasma [4] . Moreover, the VPA dose (300 mg/kg i.p. per day) applied in the in vivo studies was in the order of magnitude of the LD 50 (LD 50 = 470 mg/kg BW for i.p. administration in mice, Material Safety Data Sheet, Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Therefore, these mouse studies most probably applied much higher effective VPA concentrations than those achieved in the clinical situation in glioblastoma patients even upon dose escalation.
Likewise, a recent study on human U-87MG glioblastoma xenografts grown in chicken embryos which reported VPA-mediated impairment of angiogenesis and mesenchyme invasion by the tumor, applied VPA concentrations of 4 and 8 mM [56] . Notably, a further in vivo study transplanting primary human WK1 glioblastoma cells pre-treated with radiation and/or temozolomide and/or VPA (1 mM under serum-free conditions) orthotopically in mice observed a prolonged survival as compared to the control group (challenged with vehicle-treated WK1 cells) only in mice inoculated with radiation/VPA co-treated cells or radiation/temozolomide/VPA triple-treated cells [13] . Although suggestive of a VPAmediated radiosensitization, it has to be noted that this study [13] did not report significant longer mouse survival upon inoculation with VPA/radiation double-treated and VPA/ radiation/temozolomide triple-treated cells as compared to the survival of mice challenged with only radiation-treated and radiation/temozolomide co-treated cells, respectively.
Combined the previous in vitro and in vivo data indicate that VPA at a certain concentration may radiosensitize glioblastoma cells possibly by exceeding the threshold of relevant HDAC inhibition which results in radiosensitizing histone hyperacetylation. However, whether or not 'therapeutic' VPA concentration achieved in the clinical situation may reach this threshold might depend on the fractional expression of highly VPA-sensitive HDAC isoforms by the individual tumor. The present data on three glioblastoma cell lines and three primary glioblastoma spheroid cultures suggest that the percentage of such VPAsensitive tumors might be low.
The anticonvulsive action of VPA at 'therapeutic' concentrations is probably based on the direct interference of VPA with the glutamatergic, GABAergic and ion channel-mediated electrosignaling of excitable cells. Electrosignaling has been demonstrated to contribute to neoplastic transformation, malignant progression and therapy resistance of cancer cells (for review see [57] ). In glioblastoma cells, radiation has been shown to induce electrosignaling (for review see [58] ) that involves Ca 2+ -activated BK K + channels promoting radiogenic hypermigration [37, 38] and Ca 2+ -activated IK K + channels conferring radioresistance [35, 59] in particular in mesenchymal glioblastoma stem cells [60] . While having no effect on radioresistance in the present study, VPA (750 µM) elicited Ca 2+ signals in U251 and U-87MG cells that were paralleled by phosphorylation/degradation of the phosphatase cdc25A (a regulator of G 1 /S transition and S progression [61] ) and stabilization of the phosphorylated, inactive form of the mitose promoting factor cdc2. In accordance with inactivation of cdc25A and cdc2, VPA (750 µM) induced S and G 2 /M cell cycle arrest, respectively, in U251 and U-87MG. Since these effects were accompanied by only a slightly decreased clonogenic survival, their impact on the potential therapeutic value of VPA is most probably negligible.
The VPA-evoked Ca 2+ signals, on the other hand, stimulated in the present study the activity of BK K + channels in U251 cells. Surprisingly, VPA (750 µM) induced BK K + channel activity also in T98G cells in which VPA effects on neither Ca 2+ signaling nor cell cycle were apparent. In accordance to the reported pro-migratory function of BK K + channels [37, 38] . VPA accelerated transfilter chemotaxis of U251 and T98G cells in the present study (U-87MG cells were not tested).
Combined, the present data do not suggest a radiosensitizing effect of VPA in glioblastoma cells in general at concentrations achieved in the clinical situation. On the contrary, the observed VPA-mediated acceleration of glioblastoma cell migration might hint to an adverse side effect of VPA, which in the worst case, might boost tumor spreading and brain infiltration. 
